Another one (of particular note is the last paragraph below):
< >
Dr Stephen Franklin, chief executive of Provexis, explained: "The main
market will be those people who take aspirin every day - not because their
doctors prescribe it, but because they've heard it can help to thin the
blood.
"Unlike aspirin, which can cause gastric bleeding and different responses
in different people, CardioFlow is not a drug. It's a natural product."
Dr Franklin was reluctant to put a figure on what Provexis and the Rowett
might gain from sales of CardioFlow, but with the sale of the technology
and royalty payments for every bottle sold, the proceeds are likely to run
into millions of pounds.
He's already eyeing his next project - another form of CardioFlow, possibly
in sachet or capsule form, for medicinal use by people who have been
diagnosed with heart disease.
Provexis stock quotes
Provexis stock charts
Follow this thread
